According to the results of a proof-of-concept clinical study, Acadia Pharmaceutical Inc's drug candidate ACP-103 has been able to improve the quality of sleep in healthy older volunteers by increasing slow wave sleep.
"This suggests that ACP-103 has potential as a novel treatment for sleep maintenance insomnia. ACADIA is currently in Phase II clinical development with ACP-103 for use in schizophrenia and treatment-induced dysfunctions in Parkinson's disease, two indications with patients who frequently suffer from sleep disturbances. "
The results further demonstrate that on slow wave sleep, ACP-103 dosage is related to plasma levels and 5-HT2A-receptor antagonism. These data will be used in designing succeeding ACP-103 clinical trials.
[Source: Acadia News Release]
.jpg)
Comment Preview